002365 永安药业
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)2.638-0.6157.2286.1536.267
总资产报酬率 ROA (%)2.252-0.5165.9595.0085.185
投入资产回报率 ROIC (%)2.545-0.5916.9755.7765.911

边际利润分析
销售毛利率 (%)26.41625.86932.93522.90430.383
营业利润率 (%)14.3490.58110.4218.41111.423
息税前利润/营业总收入 (%)12.485-0.0879.0348.72011.879
净利润/营业总收入 (%)12.004-2.9219.0757.60510.117

收益指标分析
经营活动净收益/利润总额(%)62.227120.148114.97991.70091.185
价值变动净收益/利润总额(%)33.711616.8743.42518.29917.855
营业外收支净额/利润总额(%)-0.5116.6670.430-1.400-2.600

偿债能力分析
流动比率 (X)4.8714.7174.1923.6333.312
速动比率 (X)4.5174.4463.6683.1363.049
资产负债率 (%)11.72112.73213.24914.3900.162
带息债务/全部投入资本 (%)1.1882.3621.9471.4956.847
股东权益/带息债务 (%)8,195.6604,048.6294,947.5206,465.5771,330.407
股东权益/负债合计 (%)735.441663.854628.128567.241501.740
利息保障倍数 (X)-6.9720.123-6.30920.50915.929

营运能力分析
应收账款周转天数 (天)71.38062.61249.58040.93336.809
存货周转天数 (天)44.55654.78154.20933.92240.959